Brandi Ruffo, APRN
Adult Health · Greenville, SCNPI 1770954257
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,589 and has fallen 64.2% since, to $569 in 2025.
Across 257 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$888
- Abbott$608
- AbbVie$524
- Pfizer$491
- Lilly USA, LLC$299
- Amgen$230
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,445100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $888 |
| Abbott | 24 | $608 |
| AbbVie | 38 | $524 |
| Pfizer | 24 | $491 |
| Lilly USA, LLC | 21 | $299 |
| Amgen | 14 | $230 |
| AstraZeneca | 11 | $205 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $160 |
| Boehringer Ingelheim | 7 | $131 |
| Novartis | 6 | $112 |
| GSK | 7 | $107 |
| Exact Sciences | 6 | $86 |
| Esperion Therapeutics, Inc. | 4 | $76 |
| Dexcom, Inc. | 3 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Bayer | 3 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Corium, LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Halozyme Inc | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$146
- ABRYSVO$124
How this compares
$4,445 in reported general payments places this provider in the 80th percentile of 292 adult health providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $80,403 |
| JardianceEmpagliflozin | 38 | $41,016 |
| EliquisApixaban | 31 | $34,280 |
| TrulicityDulaglutide | 28 | $27,526 |
| MounjaroTirzepatide | 16 | $19,625 |
| UbrelvyUbrogepant | 12 | $17,352 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $12,598 |
| LinzessLinaclotide | 12 | $9,417 |
| Dexlansoprazole DrDexlansoprazole | 17 | $4,924 |
| Sumatriptan Succinate | 16 | $4,181 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,178 |
| SynthroidLevothyroxine Sodium | 23 | $2,585 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $2,402 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 15 | $2,129 |
| Duloxetine Hcl | 55 | $1,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $888 | $80,40341 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $299 | $47,15244 claims |
| Boehringer IngelheimJardiance | $131 | $41,01638 claims |
| PfizerEliquis | $491 | $34,28031 claims |
| AbbVieUbrelvy, Linzess, Synthroid | $524 | $29,35447 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $1,145175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 292 adult health providers in South Carolina.
Other adult health in Greenville
- Karen RobertsonGreenville$69K
- Jessica RiceGreenville$15K
- Sheri MorrisGreenville$8K
- James McKenzieGreenville$8K
- Gary SzetoGreenville$6K
- John SharkeyGreenville$6K
- Sarah BaranskiGreenville$5K
- Lynn CurryGreenville$4K
- Christine FranzeseTega Cay$30K
- Michelle PriceCharleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.